Abstract
GAS6, the product of growth arrest specific (GAS) gene 6 is a ligand for the tyrosine protein kinase receptors Axl, Tyro3 and Mer whose signaling has been implicated in cell growth, survival, adhesion and migration. Although a secreted human vitamin Kdependent protein with close structural similarity with protein S, GAS6 does not exhibit anticoagulant properties but rather may be an important regulator of vascular homeostasis and platelet signaling. GAS6 signals via its receptor tyrosine kinases and appears to modulate platelet outside-in signaling via GP αIIbβIII, playing a key role in the perpetuation of platelet aggregates and clot retraction. GAS6 is also implicated in foam cell formation and neointimal proliferation in response to vascular injury. Thus GAS6 acts at key points in the pathophysiology of atherosclerosis and thrombosis; two processes implicated in most acute cardiovascular pathology. Inhibition of GAS6 or its receptors may provide antithrombotic activity in the absence of increased bleeding and thus presents an attractive drug target. GAS6 signaling may be modulated through direct antibody inhibition, blockade of its receptors or GAS6 trapping. However, ubiquitous expression of GAS6 and its receptors and the diverse biological effects of the pathway may make selective drug targeting difficult.
Keywords: receptor tyrosine kinases, platelet response amplifier, Glycoprotein, Early region 1A gene, vascular smooth muscle cells
Current Pharmaceutical Design
Title: Growth Arrest Specific Gene (GAS) 6 Modulates Platelet Thrombus Formation and Vascular Wall Homeostasis and Represents an Attractive Drug Target
Volume: 13 Issue: 26
Author(s): Andrew O. Maree, Hani Jneid, Igor F. Palacios, Kenneth Rosenfield, Calum A. MacRae and Desmond J. Fitzgerald
Affiliation:
Keywords: receptor tyrosine kinases, platelet response amplifier, Glycoprotein, Early region 1A gene, vascular smooth muscle cells
Abstract: GAS6, the product of growth arrest specific (GAS) gene 6 is a ligand for the tyrosine protein kinase receptors Axl, Tyro3 and Mer whose signaling has been implicated in cell growth, survival, adhesion and migration. Although a secreted human vitamin Kdependent protein with close structural similarity with protein S, GAS6 does not exhibit anticoagulant properties but rather may be an important regulator of vascular homeostasis and platelet signaling. GAS6 signals via its receptor tyrosine kinases and appears to modulate platelet outside-in signaling via GP αIIbβIII, playing a key role in the perpetuation of platelet aggregates and clot retraction. GAS6 is also implicated in foam cell formation and neointimal proliferation in response to vascular injury. Thus GAS6 acts at key points in the pathophysiology of atherosclerosis and thrombosis; two processes implicated in most acute cardiovascular pathology. Inhibition of GAS6 or its receptors may provide antithrombotic activity in the absence of increased bleeding and thus presents an attractive drug target. GAS6 signaling may be modulated through direct antibody inhibition, blockade of its receptors or GAS6 trapping. However, ubiquitous expression of GAS6 and its receptors and the diverse biological effects of the pathway may make selective drug targeting difficult.
Export Options
About this article
Cite this article as:
Maree O. Andrew, Jneid Hani, Palacios F. Igor, Rosenfield Kenneth, MacRae A. Calum and Fitzgerald J. Desmond, Growth Arrest Specific Gene (GAS) 6 Modulates Platelet Thrombus Formation and Vascular Wall Homeostasis and Represents an Attractive Drug Target, Current Pharmaceutical Design 2007; 13 (26) . https://dx.doi.org/10.2174/138161207781662948
DOI https://dx.doi.org/10.2174/138161207781662948 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry NGAL is a Precocious Marker of Therapeutic Response
Current Pharmaceutical Design Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Effects of β-glucan from Aureobasidium pullulans in a Streptozotocininduced Rat Diabetes Model
Current Nutrition & Food Science Genetics and Diabetic Retinopathy
Current Diabetes Reviews Metabolic Syndrome Components in Murine Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Relation Between URIC Acid Levels and Subclinical Hypothyroidism in Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists
Current Vascular Pharmacology Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Antiretroviral Drugs and The Kidney: Dosage Adjustment and Renal Tolerance
Current Pharmaceutical Design Pulmonary Vascular Function in Insulin Resistance and Diabetes
Current Vascular Pharmacology Chronic Kidney Disease and the Risk of Cardiovascular Disease Events: A Community-Based Approach
Vascular Disease Prevention (Discontinued) Common and Less Common Peripheral Nerve Disorders Associated with Diabetes
Current Diabetes Reviews A Systematic Review on Effect of Canagliflozin in Special Population
Current Diabetes Reviews Patent Selections:
Current Biomarkers (Discontinued) Blockade of Diabetic Vascular Injury by Controlling of AGE-RAGE System
Current Drug Targets Prognostic Relevance of Metabolic Approach in Patients with Heart Failure
Current Pharmaceutical Design Pharmacological Activities and Therapeutic Potential of Kaempferitrin in Medicine for the Treatment of Human Disorders: A Review of Medicinal Importance and Health Benefits
Cardiovascular & Hematological Disorders-Drug Targets